greeksoup/ stock research

Turning Point Brands, Inc.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 7 May 2026: press release. Guidance figures: 2 raised, 1 new. The quarter’s numbers.

Key takeaways

  • Net income and EPS declined: Net income attributable to Turning Point Brands fell 19.0% to $11.7 million. Diluted EPS was $0.60 against $0.79, and adjusted diluted EPS was $0.76 against $0.91. Source
  • Adjusted EBITDA fell 6.5%: Adjusted EBITDA was $25.9 million, down 6.5% from $27.7 million, and is reconciled to net income in Schedule A. Source
  • Modern Oral sales ranges raised: Management raised both full-year 2026 Modern Oral ranges, gross and net, from the ranges given in the prior release. Source
  • Stoker's sales up 48.1%: Stoker's segment net sales rose 48.1% to $87.6 million, 70% of total net sales. Segment gross profit rose 39.1% to $47.3 million. Source
  • Zig-Zag sales fell on U.S. shipments: Zig-Zag segment net sales fell 22.4% to $36.7 million, 30% of total net sales. Management attributed the decline mainly to lower U.S. papers and wraps shipments. Source
  • SG&A rose 53.2%: SG&A rose 53.2% to $55.8 million, including Modern Oral-related sales and marketing investments and increased outbound freight costs. Source
  • Operating cash flow turned negative: Net cash used in operating activities was $22.3 million, against $17.4 million provided a year earlier. Inventory build used $21.7 million, and capital expenditures were $5.1 million. Source

“We delivered a strong first quarter, driven by continued momentum in Modern Oral and disciplined execution across the portfolio,”

Graham Purdy, President and CEO

Guidance

AreaPeriodFigureAgainst last quarter
Modern Oral gross sales Sourcefull year 2026$280-$300 millionRaised from $220-$240 million
Modern Oral net sales Sourcefull year 2026$210-$225 millionRaised from $180-$190 million
Adjusted EBITDA Sourcefull year 2026$70-$90 millionNew
Adjusted EBITDAfirst quarter 2026$24-$27 million

What changed from last quarter

  • Guidance raised: Full-year 2026 Modern Oral gross sales guidance raised to $280-$300 million from $220-$240 million. Source
  • Guidance raised: Full-year 2026 Modern Oral net sales guidance raised to $210-$225 million from $180-$190 million. Source
  • New guidance: First full-year 2026 adjusted EBITDA guidance introduced, at $70-$90 million. Source
  • New: Company cited a recently announced TKO partnership featuring UFC as part of its white pouch initiatives. Source

Results and earnings measures

  • Net sales rose 16.8%: Consolidated net sales were $124.3 million, up 16.8% from $106.4 million in the first quarter of 2025, with gross profit up 14.6% to $68.3 million. Source
  • Net income and EPS declined: Net income attributable to Turning Point Brands fell 19.0% to $11.7 million. Diluted EPS was $0.60 against $0.79, and adjusted diluted EPS was $0.76 against $0.91. Source
  • Operating income fell sharply: Operating income was $12.5 million, against $23.2 million a year earlier, as shown in the consolidated statement of income. Source
  • Adjusted EBITDA fell 6.5%: Adjusted EBITDA was $25.9 million, down 6.5% from $27.7 million, and is reconciled to net income in Schedule A. Source

Full-year guidance changes

  • Modern Oral sales ranges raised: Management raised both full-year 2026 Modern Oral ranges, gross and net, from the ranges given in the prior release. Source
  • Gross range moved up $60 million: The gross sales range moved up by $60 million at both ends. The net sales range moved up $30 million at the low end and $35 million at the high end. Source
  • First full-year EBITDA range: The company introduced a full-year 2026 adjusted EBITDA range, where the prior release gave no full-year EBITDA figure. Source

“We believe we are in the early stages of a generational shift in nicotine consumption, with significant opportunity ahead as the category continues to evolve.”

Graham Purdy, President and CEO

Segment sales and margins

  • Stoker's sales up 48.1%: Stoker's segment net sales rose 48.1% to $87.6 million, 70% of total net sales. Segment gross profit rose 39.1% to $47.3 million. Source
  • Stoker's gross margin declined: Stoker's gross margin was 54.0% against 57.5% a year earlier, which the company attributed to margin contribution from modern oral products. Source
  • Zig-Zag sales fell on U.S. shipments: Zig-Zag segment net sales fell 22.4% to $36.7 million, 30% of total net sales. Management attributed the decline mainly to lower U.S. papers and wraps shipments. Source
  • Zig-Zag gross margin rose on mix: Zig-Zag gross profit fell 18.1% to $20.9 million. Gross margin was 57.1% against 54.1%, driven primarily by product mix. Source

Modern Oral and brand investment

  • Modern Oral drove Stoker's growth: Management said triple-digit growth in Modern Oral net sales drove the Stoker's segment increase. Source
  • Investment behind white pouch: Management said it is investing in brands, commercial capabilities and consumer reach to capture meaningful share in white pouch. Source
  • SG&A rose 53.2%: SG&A rose 53.2% to $55.8 million, including Modern Oral-related sales and marketing investments and increased outbound freight costs. Source

“At the same time, our legacy brands continue to generate strong cash flow, providing the foundation to fund our strategic priorities.”

Graham Purdy, President and CEO

Costs and non-GAAP adjustments

  • Tariff cost adjustment of $5.9 million: Cost of goods sold was adjusted to exclude tariffs subject to refund, a $5.9 million item added back to adjusted EBITDA. The prior-year quarter had no such adjustment. Source
  • Stock compensation added back: Stock-based compensation of $2.9 million was added back to adjusted EBITDA, against $1.7 million a year earlier. Source
  • FDA PMTA costs fell: FDA PMTA-related costs were $0.3 million, against $1.6 million a year earlier. Source

Cash, debt and shareholder payments

  • Operating cash flow turned negative: Net cash used in operating activities was $22.3 million, against $17.4 million provided a year earlier. Inventory build used $21.7 million, and capital expenditures were $5.1 million. Source
  • Cash and net debt: Cash ended at $192.4 million, down from $222.8 million at year-end. Net debt was $101.4 million, against $77.2 million at December 31, 2025. Source
  • Liquidity of $265.0 million: Total liquidity was $265.0 million, comprised of cash and $72.6 million of asset-backed revolving credit facility capacity. Source
  • Dividends paid rose: Dividends paid were $1.7 million, against $1.4 million a year earlier, per the cash flow statement. Source
  • Outstanding shares rose: Outstanding shares were 19,367,534 at March 31, 2026, up from 19,132,384 at December 31, 2025. Source

Figures management reported

FigureReported
Modern Oral net sales Source$52.0 million, up 133%
Modern Oral share of total net sales Source42%

Risks management discussed

  • Regulatory: The company said PMTA applications can take multiple years, and two product lines are currently subject to the PMTA process. Source
  • Operational: Start-up of manufacturing lines produced non-recurring expenses, which the company excluded from adjusted results. Source

Earlier plans management reported on

  • Not stated: The prior release set a first-quarter 2026 adjusted EBITDA range; this release does not state whether it was met.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.